{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:13:52Z","timestamp":1792761232373,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The aim of this study was to prospectively describe evolution of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake of extrapulmonary tuberculosis (TB) throughout the course of TB treatment in HIV patients to evaluate\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT as a monitoring tool of treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed baseline FDG PET\/CT, PET-2 after 2 months, and PET-3 at the end of TB treatment in 18 HIV\/TB patients. We correlated evolution of FDG uptake with clinical outcome of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 2 months of treatment, 78% of the patients had a significant metabolic response. Lymph node (LN) metabolic response was heterogeneous, with 57% of LN sites showing decreased SUVmax and 41% showing unchanged FDG uptake. Organs other than LNs showed more homogeneous response. The FDG PET\/CT performed at the end of TB treatment showed a complete response of all infected organs and a drastic response in terms of active LNs in 95% of the patients (SUVmax mean decrease = 85%, median = 100%). A complete metabolic response after TB treatment was seen in only 47% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In difficult-to-treat entities such as extrapulmonary TB in HIV patients, FDG PET\/CT is a potential tool in monitoring TB treatment response and should be explored in larger studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000002187","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T17:50:45Z","timestamp":1531763445000},"page":"635-640","source":"Crossref","is-referenced-by-count":18,"title":["Prospective Serial FDG PET\/CT During Treatment of Extrapulmonary Tuberculosis in HIV-Infected Patients"],"prefix":"10.1097","volume":"43","author":[{"given":"Charlotte","family":"Martin","sequence":"first","affiliation":[{"name":"Infectious Diseases Department, Saint-Pierre University Hospital, Brussels;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Castaigne","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Grand Hopital de Charleroi, Charleroi;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Vierasu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Hopital de Jolimont-Lobbes, Lobbes; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Garcia","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Saint-Pierre University Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Wyndham-Thomas","sequence":"additional","affiliation":[{"name":"AIDS Reference Center and Immunodeficiency Treatment Unit, Erasme Hospital, Brussels, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"de Wit","sequence":"additional","affiliation":[{"name":"Infectious Diseases Department, Saint-Pierre University Hospital, Brussels;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230925","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1126\/science.1086845","article-title":"Antiretroviral drugs for tuberculosis control in the era of HIV\/AIDS","volume":"301","year":"2003","journal-title":"Science"},{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MNM.0b013e3283163b92","article-title":"What impact can fluorine-18 fluorodeoxyglucose PET\/computed tomography have on HIV\/AIDS and tuberculosis pandemic","volume":"30","year":"2009","journal-title":"Nucl Med Commun"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1097\/01.aids.0000176211.08581.5a","article-title":"How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control","volume":"19","year":"2005","journal-title":"AIDS"},{"key":"bib4-20230925","first-page":"1","article-title":"The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia","volume":"96","year":"1993","journal-title":"J Trop Med Hyg"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/00002030-199010000-00006","article-title":"Extrapulmonary and disseminated tuberculosis in HIV-1\u2013seropositive patients presenting to the acute medical services in Nairobi","volume":"4","year":"1990","journal-title":"AIDS"},{"key":"bib6-20230925","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents","volume":"58","year":"2009","journal-title":"MMWR"},{"key":"bib7-20230925","first-page":"149","article-title":"Diagnosing tuberculosis in HIV-infected patients: challenges and future prospects","volume":"81\u201382","year":"2007","journal-title":"Br Med Bull"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/hiv.12030","article-title":"Role and interpretation of fluorodeoxyglucose\u2013positron emission tomography\/computed tomography in HIV-infected patients with fever of unknown origin: a prospective study","volume":"14","year":"2013","journal-title":"HIV Med"},{"key":"bib9-20230925","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MNM.0b013e328310b38d","article-title":"Clinical value of FDG-PET\/CT for the diagnosis of human immunodeficiency virus\u2013associated fever of unknown origin: a retrospective study","volume":"30","year":"2009","journal-title":"Nucl Med Commun"},{"key":"bib10-20230925","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/RLU.0000000000001102","article-title":"18F-FDG PET\/CT in the initial assessment and for follow-up in patients with tuberculosis","volume":"41","year":"2016","journal-title":"Clin Nucl Med"},{"key":"bib11-20230925","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1128\/AAC.00789-09","article-title":"Non-invasive pulmonary [18F]-2-fluoro-deoxy-d-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"bib12-20230925","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-00034924","article-title":"Impact of FDG PET on the management of TBC treatment. A pilot study","volume":"49","year":"2010","journal-title":"Nuklearmedizin"},{"key":"bib13-20230925","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00259-008-1009-5","article-title":"Usefulness of 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis","volume":"36","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20230925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/RLU.0b013e31815c5128","article-title":"Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography","volume":"33","year":"2008","journal-title":"Clin Nucl Med"},{"key":"bib15-20230925","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1007\/s00259-010-1587-x","article-title":"FDG-PET\/CT in infections: the imaging method of choice?","volume":"37","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20230925","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13139-011-0114-8","article-title":"Monitoring therapeutic response in a case of extrapulmonary tuberculosis by serial F-18 FDG PET\/CT","volume":"46","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"bib17-20230925","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.tube.2007.05.013","article-title":"Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response","volume":"87","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"key":"bib18-20230925","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"bib19-20230925","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/cid\/ciu094","article-title":"National Institutes of Health; Centers for Disease Control and Prevention; HIV Medicine Association of the Infectious Diseases Society of America. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents","volume":"58","year":"2014","journal-title":"Clin Infect Dis"},{"key":"bib20-20230925","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2011.00954.x","article-title":"British HIV Association guidelines for the treatment of TB\/HIV coinfection 2011","volume":"12","year":"2011","journal-title":"HIV Med"},{"key":"bib21-20230925","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3109\/02841851.2010.504744","article-title":"FDG PET\/CT for therapeutic response monitoring in multi-site non-respiratory tuberculosis","volume":"51","year":"2010","journal-title":"Acta Radiol"},{"key":"bib22-20230925","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2466-13-14","article-title":"18-Fluorodeoxyglucose positron emission tomography for tuberculosis diagnosis and management: a case series","volume":"13","year":"2013","journal-title":"BMC Pulm Med"},{"key":"bib23-20230925","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.5588\/ijtld.12.0010","article-title":"(18)F-FDG PET\/CT in tuberculosis: an early non-invasive marker of therapeutic response","volume":"16","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"bib24-20230925","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/RLU.0000000000001895","article-title":"SUV as a possible predictor of disease extent and therapy duration in complex tuberculosis","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib25-20230925","first-page":"49","article-title":"FDG-PET imaging in HIV infection and tuberculosis","volume":"43","year":"2013","journal-title":"Semin Nucl Med"},{"key":"bib26-20230925","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.110.083709","article-title":"Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIV-associated tuberculosis","volume":"52","year":"2011","journal-title":"J Nucl Med"},{"key":"bib27-20230925","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MCP.0000000000000043","article-title":"Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET\/CT","volume":"20","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"bib28-20230925","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1086\/429317","article-title":"Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis","volume":"40","year":"2005","journal-title":"Clin Infect Dis"},{"key":"bib29-20230925","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.nucmedbio.2017.04.003","article-title":"Clinical usefulness of 18F-FDG PET\/CT for initial staging and assessment of treatment efficacy in patients with lymph node tuberculosis","volume":"50","year":"2017","journal-title":"Nucl Med Biol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201809000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T01:06:53Z","timestamp":1695604013000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201809000-00001"}},"subtitle":["An Exploratory Study"],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002187","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}